alexsl
- UBS upgraded Amgen (AMGN) to purchase from impartial saying that two of its late-stage property, MariTide for weight problems and olpasiran for cardiovascular threat discount, ought to drive progress via 2030.
- The Swiss financial institution additionally raised its worth goal to $380 from $317 prior (15% upside
